CII proposes action points for strengthening the healthcare, pharma sectors amid COVID-19 crisis

Image
ANI
Last Updated : Mar 19 2020 | 4:15 PM IST

The Confederation of India Industry (CII) said on Thursday that hospitals in larger cities and district hospitals in smaller cities and towns should be designated as COVID hospital for testing and isolation of patients.

The private sector can support the government in medical facilities, pharmaceuticals and medical equipment, it said.CII further suggested the adoption of widescale E-ICU/teleconsultation to tackle the spread of COVID-19, especially in its phase three and four.

On pharmaceuticals, CII said the current situation makes a compelling case for the government to declare active pharma ingredients (APIs) as a strategic sector as most inputs are imported.

Firms for which capacity utilisation is 40 per cent may be permitted to produce APIs which are being imported. Approvals for new investments should be fast-tracked.

CII proposed that blanket environment permission be provided to manufacture any API on submission of self-certification to comply with pollution load requirements. The outbreak could lead to a significant shortage of supply in the medical technology sector as well, especially for critical medicines and medical devices like thermometers, nebulisers and glucometers.

The medical devices market too is heavily import-dependent at about 70 to 80 per cent with imaging equipment (CT and MRI scanners), cardiac stents, orthopedic implants, glucometers and critical care equipment cornering a large share.

Many raw materials and components are imported from China.While the real impact on industry is likely to be visible only after April, domestic manufacturer's capacities will need to be bolstered which will likely become reliable sources amid global shortages, said CII.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 19 2020 | 4:06 PM IST

Next Story